COVID-19 and Type 2 Diabetes Mellitus: HCQ may be the Holy Grail

Author(s): Rimesh Pal, Manoj K. Bhasin, Sanjay K. Bhadada*

Journal Name: Infectious Disorders - Drug Targets
Formerly Current Drug Targets - Infectious Disorders

Volume 21 , Issue 5 , 2021


Article ID: e270421186842
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

The novel coronavirus disease (COVID-19) is on the rampage claiming over 297000 lives globally. Disease severity and mortality rates are higher in patients with underlying diabetes mellitus. Till date, there exists no effective vaccine or therapy against COVID-19. However, with limited clinical data, HCQ is being used for treatment and prophylaxis in patients with COVID-19. HCQ is also used as an anti-diabetic drug and has been approved in India as an adjunct to diet and exercise to improve glycemic control of patients with Type 2 Diabetes Mellitus (T2DM) on metformin and sulfonylurea combination in Type 2 Diabetes Mellitus (T2DM). Thus, although indiscriminate use of HCQ is fraught with danger, HCQ can be considered as a third-line add on anti-diabetic agent in people with T2DM amid the ongoing pandemic after having ruled out the contraindications to the use of this drug.

Keywords: HCQ, diabetes mellitus, COVID-19, T2DM, vaccine, pandemic, SARS-CoV-2.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 21
ISSUE: 5
Year: 2021
Published on: 13 October, 2020
Article ID: e270421186842
Pages: 4
DOI: 10.2174/1871526520666201013160803
Price: $65

Article Metrics

PDF: 107